Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Personal medicine—the new banking crisis

Nature Biotechnology volume 30, pages 141–147 (2012)Cite this article

Subjects

An Erratum to this article was published on 07 May 2012

This article has been updated

Abstract

As the healthcare industry moves from a twentieth century approach of providing treatments of last resort to a future of individualized medicine, biobanks will play a pivotal role in this transition. Yet at the cutting edge of biobanking research are new ethical, social and policy challenges beyond those familiar to basic biomedical research.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Biobanks around the world.
Figure 2: Global market value of the demand for human biospecimens and related services.

Change history

  • 24 February 2012

    In the version of the article originally published, the citation in Figure 1 was given as ref. 14; it should be ref. 2. In Table 1, CARTaGENE was misspelled, and the descriptions in column 3 of this repository, BioVu's and the International HapMap were incorrect: CARTaGENE should be described as “a repository of socio-demographic, health data and biological samples from 20,000 citizens of the province of Quebec in Canada”; BioVu's description should read “Repository of DNA samples and de-identified health information from the Vanderbilt University Medical Center's electronic system”; and the International HapMap description should read “International collaboration with the ultimate goal of developing a haplotype map of the human genome.” In addition, the amount of the Havasupai settlement was incorrectly stated to be $700 million. It should read $700,000. Finally, the work of Simon et al. (ref. 8). on biobank consent models was incorrectly described. The text should read, “For example, a recent US focus group and survey study found a public that preferred a broad approach to consent over ones involving additional choices. But the preference was marginal, thus noting the lack of consensus on these issues. Indeed, as noted by the authors of the study: '54% of our survey and 42% of our focus group participants could be seen as preferring a control/choice-promoting model (e.g., categorical or study-specific consent) over a control/choice demoting model (e.g., broad consent)8'.” The errors have been corrected in the HTML and pdf versions of the article.

References

  1. Hoffmann, T.J. et al. Next generation genome-wide association tool: design and coverage of a high-throughput European-optimized SNP array. Genomics 98, 79–89 (2011).

    Article  CAS  Google Scholar 

  2. Melsin, E.M. & Goodman, K. Biobanks and electronic health records: ethical and policy challenges in the genomic age. (Indiana University Center for Applied Cybersecurity Research, Indianapolis, October, 2009). <http://hdl.handle.net/1805/2129>

  3. Vaught, J., Rodgers, J., Carolin, T. & Compton, C. Biobankonomics: developing a sustainable business model approach for the formation of a human tissue biobank. J. Natl. Cancer Inst. Monogr. 42, 24–31 (2011).

    Article  Google Scholar 

  4. Institute of Medicine. Establishing Precompetitive Collaborations to Stimulate Genomics-Driven Drug Development: Workshop Summary (National Academies Press, Washington, DC, 2011).

  5. Anonymous. Few Americans using 'e-' medical records. Harris Interactive, June 17, 2010. <http://www.harrisinteractive.com/NewsRoom/HarrisPolls/tabid/447/mid/1508/articleId/414/ctl/ReadCustom%20Default/Default.aspx>

  6. Mello, M.M. & Wolf, L.E. The Havasupai Indian tribe case—lessons for research involving stored biologic samples. N. Engl. J. Med. 363, 204–207 (2010).

    Article  CAS  Google Scholar 

  7. United Nations Educational, Scientific and Cultural Organization (UNESCO). Report of the International Bioethics Committee of UNESCO (IBC) on Consent. (IBC, 2008). <http://unesdoc.unesco.org/images/0017/001781/178124e.pdf>

  8. Simon, C.M. et al. Active choice but not too active: public perspectives on biobank consent models. Genet. Med. 13, 821–831 (2011).

    Article  Google Scholar 

  9. Toga, A. Neuroimage databases: the good, the bad and the ugly. Nat. Rev. Neurosci. 3, 302–309 (2002).

    Article  CAS  Google Scholar 

  10. Campbell, E.G. et al. Data withholding in academic genetics. J. Am. Med. Assoc. 287, 473–480 (2002).

    Article  Google Scholar 

  11. National Institutes of Health Roadmap Working Group. Reengineering the clinical enterprise. (NIH, 1 June 2004). <https://commonfund.nih.gov/pdf/rtrc_interimreport.pdf>

  12. National Bioethics Advisory Commission (NBAC). Research Involving Human Biological Materials: Ethical Issues and Policy Guidance, Vol. 1 (NBAC Rockville, MD: 1999).

  13. Illes, J. et al. Ethics: Incidental findings in brain imaging research. Science, 311, 783–784 (2006).

    Article  CAS  Google Scholar 

  14. Washington University v. Catalona, No. 4:03CV1065 (E. Dist. Mo. April 14, 2006), on appeal Nos. 06–2286 & 06–2301 (8th Cir.).

  15. Caulfield, T. The biobanking quandary: getting and withdrawing consent. Harvard Health Policy Review 12, 21–24 (2011).

    Google Scholar 

  16. Salvaterra, E. et al. Banking together. EMBO Rep. 9, 307–313 (2008).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

C.T.S. acknowledges support from the Stanford Center for Biomedical Ethics. T.C. thanks AllerGen (National Centres of Excellence program) the Cancer Stem Cell Consortium and the ICDC, University of Alberta. J.I. and E.B.'s contributions to this paper were enabled by NIH/National Institute of Mental Health R01 no. MH 9R01MH84282, Canadian Institutes of Health Research/Institute of Neurosciences, Mental Health and Addiction no. CNE85117, the British Columbia Knowledge Development Fund and the Canadian Foundation for Innovation. J.I. is a member of the NIH, National Human Genome Research Institute grant no. 2-R01-HG003178.

Author information

Authors and Affiliations

  1. Christopher Thomas Scott is at the Center for Biomedical Ethics, Stanford, California, USA and the National Core for Neuroethics, The University of British Columbia, Vancouver, Canada.,

    Christopher Thomas Scott

  2. Timothy Caulfield is at the Faculty of Law and School of Public Health, Health Law and Science Policy Group, University of Alberta, Edmonton, Alberta, Canada.,

    Timothy Caulfield

  3. Emily Borgelt and Judy Illes are at the National Core for Neuroethics, The University of British Columbia, Vancouver, Canada.,

    Emily Borgelt & Judy Illes

Authors
  1. Christopher Thomas Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timothy Caulfield
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emily Borgelt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Judy Illes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher Thomas Scott.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Scott, C., Caulfield, T., Borgelt, E. et al. Personal medicine—the new banking crisis. Nat Biotechnol 30, 141–147 (2012). https://doi.org/10.1038/nbt.2116

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2116

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research